News
Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
2012
-
Dec 14, 2012
Notice concerning adoption of
International Financial Reporting Standards (IFRS)
[PDF 53KB] -
Dec 13, 2012
Organizational and Personnel Changes
[PDF 146KB] -
Nov 28, 2012
Chugai Pharma Manufacturing to Conclude an Agreement with Fujieda City
to Offer Help During Times of Disaster
[PDF 349KB] -
Nov 27, 2012
Co-Development and Co-Marketing Agreement for
the Glycoengineered Type II Anti-CD20 Monoclonal Antibody,
“GA101 (obinutuzumab)”
[PDF 17KB] -
Nov 26, 2012
Notice Concerning the Passing Away
of a Chugai Pharmaceutical Director
[PDF 162KB] -
Nov 12, 2012
ADACTA Study Showed ACTEMRA Improved Signs and Symptoms
of Rheumatoid Arthritis Significantly More Than Adalimumab as a
Single-Agent Therapy
[PDF 214KB] -
Nov 05, 2012
Eli Lilly Japan and Chugai to Terminate
Co-Marketing Agreement of “EVISTA® tablet 60mg,”
a Treatment for Osteoporosis in Postmenopausal Women
[PDF 144KB] -
Nov 01, 2012
Supply Plan of "Tamiflu®" Anti-influenza Drug for the 2012-2013 Season
[PDF 133KB] -
Oct 26, 2012
License Agreement of SGLT2 Inhibitor “CSG452” in Japan
[PDF 96KB] -
Oct 19, 2012
Chugai Presents an Anti-Cancer Charity
“WAHAHA HONPO Special Live Show”
[PDF 200KB] -
Oct 19, 2012
Chugai Succeeds in Establishing Stable Cell Lines of Cancer
Stem Cell for the First Time
- A step forward in elucidating the mechanisms of recurrence/metastasis and drug
resistance of cancer and in the development of a new therapeutic agent - [PDF 231KB] -
Oct 16, 2012
F. Hoffmann-La Roche Announces Third Quarter Sales 2012
[PDF 22KB] -
Oct 15, 2012
FDA Approves Expanded Indication for ACTEMRA®
in Rheumatoid Arthritis
[PDF 187KB] -
Oct 05, 2012
Anti-Cancer Agent “Avastin®,”
Application for Approval of Additional Indication of Ovarian Cancer
[PDF 177KB] -
Oct 01, 2012
Novel Concept for Treatment of Hemophilia A
Published in Nature Medicine
-Bispecific antibody substitutes for the function of blood coagulation factor VIII- [PDF 189KB] -
Sep 27, 2012
Contribution of Para-transit Vehicles to Welfare Services
[PDF 224KB] -
Sep 19, 2012
Anti-Cancer Agent “Avastin®,”
Application for Approval of Additional Indication of
Recurrent Glioblastoma
[PDF 177KB] -
Aug 31, 2012
Resignation of a Director
[PDF 172KB] -
Aug 10, 2012
Synthetic Antibacterial Agent, Bactramin®
Approved for Additional Indication of
“Treatment and Prevention of Pneumocystis Pneumonia”
[PDF 117KB] -
Jul 27, 2012
Roche Reports Second Positive Study of RoACTEMRA Given by
Subcutaneous Injection to Patients with Rheumatoid Arthritis
[PDF 213KB] -
Jul 26, 2012
F. Hoffmann-La Roche Announces Second Quarter Sales 2012
[PDF 21KB] -
Jul 18, 2012
New Drug Application Filed for Ibandronate Sodium Hydrate Injection,
Bisphosphonate Antiresorptive Agent
[PDF 19KB] -
Jul 17, 2012
Opening of Chugai’s Research Subsidiary
“Chugai Pharmabody Research Pte. Ltd.” in Singapore
[PDF 199KB] -
Jun 26, 2012
Anti-Cancer Agent “Tarceva®,”
Application for Approval of Additional Indication of
Non-Small Cell Lung Cancer (First Line Therapy)
[PDF 170KB] -
Jun 07, 2012
Launch of an Orphan Drug, “Pulmozyme®,”
a Recombinant Human Deoxyribonuclease I (rhDNase)
[PDF 366KB] -
Jun 06, 2012
Roche’s RoACTEMRA
Improved Rheumatoid Arthritis Signs and Symptoms
Significantly More than Adalimumab as Single-Agent Therapy
[PDF 194KB] -
May 25, 2012
New Drug Application Filed for Anti-Cancer Agent “Pertuzumab”
for the Treatment of HER2-Positive Metastatic or Recurrent
Breast Cancer
[PDF 189KB] -
May 11, 2012
Chugai Renews its “Human Body System” Website
-Now easier to understand with abundant illustrations and captions- [PDF 162KB] -
May 10, 2012
Determination of Terms and Conditions of Stock Options (Stock Acquisition Rights)
[PDF 50KB] -
May 07, 2012
Roche Reports Positive Study of RoACTEMRA
Given by Subcutaneous Injection
[PDF 244KB] -
Apr 24, 2012
Issuance of Stock Options (Stock Acquisition Rights)
[PDF 79KB] -
Apr 12, 2012
F. Hoffmann-La Roche Announces First Quarter Sales 2012
[PDF 21KB] -
Apr 11, 2012
Chugai Establishes Endowed Course at Keio University
– “Health” related issues to be extracted and searched for solutions –
[PDF 150KB] -
Mar 30, 2012
Approval of an Orphan Drug, “Pulmozyme®,”
a Recombinant Human Deoxyribonuclease I (rhDNase)
[PDF 243KB] -
Mar 02, 2012
Roche’s RoACTEMRA Monotherapy Showed Superior Improvement in Rheumatoid Arthritis Signs and Symptoms Versus Adalimumab Monotherapy
[PDF 249KB] -
Feb 21, 2012
FDA Accepts Supplemental Biologics License Application Submitted for
ACTEMRA®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody,
Regarding Adult Rheumatoid Arthritis Indication
[PDF 181KB] -
Feb 13, 2012
Synthetic Antibacterial Agent, Bactramin®
Filed for Additional Indication By
“Application Based on Evidence in the Public Domain”
[PDF 94KB] -
Feb 07, 2012
Anti-Cancer Agent, Tarceva®
Condition for Approval (All Patients Surveillance) Partially Removed in Japan for
“Nonresectable Recurrent and Advanced Non-small Cell Lung Cancer
which is Aggravated Following Chemotherapy”
[PDF 173KB] -
Feb 01, 2012
Notice of Changes to Representative Directors
[PDF 50KB] -
Feb 01, 2012
Personnel Changes
[PDF 54KB] -
Feb 01, 2012
Organizational and Personnel Changes
[PDF 151KB] -
Feb 01, 2012
Notice of Partial Amendments to the Articles of Incorporation
[PDF 50KB] -
Feb 01, 2012
F. Hoffmann-La Roche Announces Financial Results for Fiscal 2011
[PDF 40KB]